Bevacizumab clearance through the iridocorneal angle following intravitreal injection in a rat model

Experimental Eye Research

Volumn 145, Issue , 2016, Pages 412-416

  Gal Or, Orly ^a   Dotan, Assaf ^a   Dachbash, Mor ^a   Tal, Kfir ^a   Nisgav, Yael ^a   Weinberger, Dov ^a,b   Ehrlich, Rita ^a,b   Livnat, Tami ^a,b  

^a RABIN MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Bevacizumab; Clearance; Intraocular pressure; Schlemm's canal; Trabecular meshwork

Indexed keywords

BEVACIZUMAB; ANGIOGENESIS INHIBITOR; VASCULOTROPIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AQUEOUS HUMOR OUTFLOW; ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; ENDOTHELIUM CELL; IMMUNODETECTION; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; INTRAOCULAR HYPERTENSION; LASER COAGULATION; MALE; NONHUMAN; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; RAT; SCHLEMM CANAL; SUBRETINAL NEOVASCULARIZATION; TRABECULAR MESHWORK; ANIMAL; ANTERIOR EYE CHAMBER; BROWN NORWAY RAT; CHEMISTRY; CHOROIDAL NEOVASCULARIZATION; CORNEA; DISEASE MODEL; INTRAVITREAL DRUG ADMINISTRATION; IRIS; METABOLISM; TIME FACTOR;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTERIOR CHAMBER; BEVACIZUMAB; CHOROIDAL NEOVASCULARIZATION; CORNEA; DISEASE MODELS, ANIMAL; INTRAVITREAL INJECTIONS; IRIS; MALE; RATS; RATS, INBRED BN; TIME FACTORS; TRABECULAR MESHWORK; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84960933284     PISSN: 00144835     EISSN: 10960007     Source Type: Journal    
DOI: 10.1016/j.exer.2016.02.006     Document Type: Article

References (37)

1. Abedi G., Adelman R.a, Salim S. Incidence and management of elevated intraocular pressure with antivascular endothelial growth factor agents. Semin. Ophthalmol. 2013, 28:126-130. 10.3109/08820538.2013.771195.
2. Adelman R.a, Zheng Q., Mayer H.R. Persistent ocular hypertension following intravitreal bevacizumab and ranibizumab injections. J. Ocul. Pharmacol. Ther. 2010, 26:105-110. 10.1089/jop.2009.0076.
3. Antes R., Salomon-Zimri S., Beck S.C., Garcia Garrido M., Livnat T., Maharshak I., Kadar T., Seeliger M., Weinberger D., Michaelson D.M. VEGF mediates ApoE4-induced neovascularization and synaptic pathology in the choroid and retina. Curr. Alzheimer Res. 2015, 12:323-334.
4. Bakri S.J., Ekdawi N.S. Intravitreal silicone oil droplets after intravitreal drug injections. Retina 2008, 28:996-1001. 10.1097/IAE.0b013e31816c6868.
5. Bakri S.J., McCannel C.a., Edwards A.O., Moshfeghi D.M. Persistent ocular hypertension following intravitreal ranibizumab. Graefe's Arch. Clin. Exp. Ophthalmol. 2008, 246:955-958. 10.1007/s00417-008-0819-2.
6. Bakri S.J., Snyder M.R., Reid J.M., Pulido J.S., Singh R.J. Pharmacokinetics of intravitreal bevacizumab (avastin). Ophthalmology 2007, 114:855-859. 10.1016/j.ophtha.2007.01.017.
7. Barzelay A., Lowenstein A., George J., Barak A. Influence of non-toxic doses of bevacizumab and ranibizumab on endothelial functions and inhibition of angiogenesis. Curr. Eye Res. 2010, 35:835-841. 10.3109/02713683.2010.489727.
8. Bressler N.M. Antiangiogenic approaches to age-related macular degeneration today. Ophthalmology 2009, 116. 10.1016/j.ophtha.2009.06.048.
9. Choi D.Y., Ortube M.C., McCannel C.A., Sarraf D., Hubschman J.-P., McCannel T.A., Gorin M.B. Sustained elevated intraocular pressures after intravitreal injection of bevacizumab, ranibizumab, and pegaptanib. Retina 2011, 31:1028-1035. 10.1097/IAE.0b013e318217ffde.
10. Dratviman-Storobinsky O., Lubin B.-C.R.A., Hasanreisoglu M., Goldenberg-Cohen N. Effect of subconjuctival and intraocular bevacizumab injection on angiogenic gene expression levels in a mouse model of corneal neovascularization. Mol. Vis. 2009, 15:2326-2338.
11. Georgopoulos M., Polak K., Prager F., Prünte C., Schmidt-Erfurth U. Characteristics of severe intraocular inflammation following intravitreal injection of bevacizumab (Avastin). Br. J. Ophthalmol. 2009, 10.1136/bjo.2008.138479.
12. Good T.J., Kimura A.E., Mandava N., Kahook M.Y. Sustained elevation of intraocular pressure after intravitreal injections of anti-VEGF agents. Br. J. Ophthalmol. 2011, 95:1111-1114. 10.1136/bjo.2010.180729.
13. Heiduschka P., Fietz H., Hofmeister S., Schultheiss S., Mack A.F., Peters S., Ziemssen F., Niggemann B., Julien S., Bartz-Schmidt K.U., Schraermeyer U. Penetration of bevacizumab through the retina after intravitreal injection in the monkey. Investig. Ophthalmol. Vis. Sci. 2007, 48:2814-2823. 10.1167/iovs.06-1171.
14. Hoang Q.V., Tsuang A.J., Gelman R., Mendonca L.S., Della Torre K.E., Jung J.J., Freund K.B. Clinical predictors of sustained intraocular pressure elevation due to intravitreal anti-vascular endothelial growth factor therapy. Retina 2013, 33:179-187. 10.1097/IAE.0b013e318261a6f7.
15. Iturralde D., Spaide R.F., Meyerle C.B., Klancnik J.M., Yannuzzi L.A., Fisher Y.L., Sorenson J., Slakter J.S., Freund K.B., Cooney M., Fine H.F. Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short-term study. Retina 2006, 26:279-284.
16. Jalil A., Fenerty C., Charles S. Intravitreal bevacizumab (Avastin) causing acute glaucoma: an unreported complication. Eye Lond. 2007, 21:1541. 10.1038/sj.eye.6703018.
17. Kahook M.Y., Kimura A.E., Wong L.J., Ammar D.A., Maycotte M.A., Mandava N. Sustained elevation in intraocular pressure associated with intravitreal bevacizumab injections. Ophthalmic Surg. Lasers Imaging 2009, 40:293-295.
18. Kahook M.Y., Liu L., Ruzycki P., Mandava N., Carpenter J.F., Petrash J.M., Ammar D.A. High-molecular-weight aggregates in repackaged bevacizumab. Retina 2010, 30:887-892. 10.1097/IAE.0b013e3181d50cea.
19. Kim J.E., Mantravadi A.V., Hur E.Y., Covert D.J. Short-term intraocular pressure changes immediately after intravitreal injections of anti-vascular endothelial growth factor agents. Am. J. Ophthalmol. 2008, 146:930-934. 10.1016/j.ajo.2008.07.007.
20. Kim S.J., Toma H.S., Barnett J.M., Penn J.S. Ketorolac inhibits choroidal neovascularization by suppression of retinal VEGF. Exp. Eye Res. 2010, 91:537-543. 10.1016/j.exer.2010.07.011.
21. Kubota T., Okabe H., Hisatomi T., Yamakiri K., Sakamoto T., Tawara A. Ultrastructure of the trabecular meshwork in secondary glaucoma eyes after intravitreal triamcinolone acetonide. J. Glaucoma 2006, 10.1097/00061198-200604000-00007.
22. Levkovitch-Verbin H., Quigley H.A., Martin K.R.G., Valenta D., Baumrind L.A., Pease M.E. Translimbal laser photocoagulation to the trabecular meshwork as a model of glaucoma in rats. Investig. Ophthalmol. Vis. Sci. 2002, 43:402-410.
23. Liu L., Ammar D.A., Ross L.A., Mandava N., Kahook M.Y., Carpenter J.F. Silicone oil microdroplets and protein aggregates in repackaged bevacizumab and ranibizumab: effects of long-term storage and product mishandling. Investig. Ophthalmol. Vis. Sci. 2011, 52:1023-1034. 10.1167/iovs.10-6431.
24. Morshedi R.G., Ricca A.M., Wirostko B.M. Ocular hypertension following intravitreal antivascular endothelial growth factor therapy: review of the literature and possible role of nitric oxide. J. Glaucoma 2014, 10.1097/IJG.0000000000000173.
25. Nomoto H., Shiraga F., Kuno N., Kimura E., Fujii S., Shinomiya K., Nugent A.K., Hirooka K., Baba T. Pharmacokinetics of bevacizumab after topical, subconjunctival, and intravitreal administration in rabbits. Investig. Ophthalmol. Vis. Sci. 2009, 50:4807-4813. 10.1167/iovs.08-3148.
26. Paylakhi S.H., Yazdani S., April C., Fan J.-B., Moazzeni H., Ronaghi M., Elahi E. Non-housekeeping genes expressed in human trabecular meshwork cell cultures. Mol. Vis. 2012, 18:241-254.
27. Perkumas K.M., Stamer W.D. Protein markers and differentiation in culture for Schlemm's canal endothelial cells. Exp. Eye Res. 2012, 96:82-87. 10.1016/j.exer.2011.12.017.
28. Peters S., Heiduschka P., Julien S., Ziemssen F., Fietz H., Bartz-Schmidt K.U., Schraermeyer U. Ultrastructural findings in the primate eye after intravitreal injection of bevacizumab. Am. J. Ophthalmol. 2007, 143. 10.1016/j.ajo.2007.03.007.
29. Qv H., Ls M., Ke T., Jj J., Aj T., Kb F. Effect on intraocular pressure in patients receiving unilateral intravitreal anti-vascular endothelial growth factor injections. Ophthalmology 2012, 119:321-326. 10.1016/j.ophtha.2011.08.011.
30. Shahar J., Avery R.L., Heilweil G., Barak A., Zemel E., Lewis G.P., Johnson P.T., Fisher S.K., Perlman I., Loewenstein A. Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin). Retina 2006, 26:262-269. 10.1097/00006982-200603000-00002.
31. Shinzato M., Yamashiro Y., Miyara N., Iwamatsu A., Takeuchi K., Umikawa M., Bayarjargal M., Kariya K.I., Sawaguchi S. Proteomic analysis of the trabecular meshwork of rats in a steroid-induced ocular hypertension model: downregulation of type I collagen C-propeptides. Ophthalmic Res. 2007, 39:330-337. 10.1159/000109989.
32. Simha A., Braganza A., Abraham L., Samuel P., Lindsley K. Anti-vascular endothelial growth factor for neovascular glaucoma. Cochrane Database Syst. Rev. 2009, 10.1002/14651858.CD007920.
33. Singh R.S.J., Kim J.E. Ocular hypertension following intravitreal anti-vascular endothelial growth factor agents. Drugs Aging 2012, 29:949-956. 10.1007/s40266-012-0031-2.
34. Sniegowski M., Mandava N., Kahook M.Y. Sustained intraocular pressure elevation after intravitreal injection of bevacizumab and ranibizumab associated with trabeculitis. Open Ophthalmol. J. 2010, 4:28-29. 10.2174/1874364101004010028.
35. Spaide R.F., Fisher Y.L. Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina Phila. PA. 2006.
36. Stewart M.W. Pharmacokinetics, pharmacodynamics and pre-clinical characteristics of ophthalmic drugs that bind VEGF. Expert Rev. Clin. Pharmacol. 2014, 7:167-180. 10.1586/17512433.2014.884458.
37. Tseng J.J., Vance S.K., Della Torre K.E., Mendonca L.S., Cooney M.J., Klancnik J.M., Sorenson J.A., Freund K.B. Sustained increased intraocular pressure related to intravitreal antivascular endothelial growth factor therapy for neovascular age-related macular degeneration. J. Glaucoma 2012, 10.1097/IJG.0b013e31820d7d19.